Ablynx raises US$230m
Belgian nanobody producer Ablynx closes an initial public offering of American Depositary Shares at Nasdaq totalling US$200m plus a fully exercised greenshoe option amounting aggregate gross proceeds to US$230.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2190 entries already.
Entries by Thomas Gabrielczyk
CPHI Worldwide expands outreach
The world’s largest event for pharma professionals, CPHI worldwide, will see an expansion to the rapidly-growing field of biologics next year in Madrid
Insight into biomarkers
AYOXXA’s LUNARIS platform:?In a case study "Translational proteomics: a new perspective for
ophthalmology research, Ayoxxa gives insights into the capabilities of its Lunaris multiplex protein
analysis platform.
300 jobs more: US company expands its Irish campus
US biotech company Regeneron Pharmaceuticals revealed plans to create some 300 new jobs in Ireland’s Limerick County. The jobs form part of a US$100m (€85m) expansion plan for the company’s campus there.
Immunethep receives grant from Gates Foundation
Portuguese biotech company Immunethep has convinced the Bill & Melinda Gates Foundation to hand out a grant to test its antibody against the bacterial extracellular virulence factor GAPDH.
EU researchers unveil how T cell dysfunction triggers MS
French and British scientists have revealed insight into how a critical immune regulatory pathway contributes to the development of multiple sclerosis (MS), potentially paving the way toward future immunotherapies for the debilitating condition.
Biofuels: study challenges EU’s tank or table paradigm
A comprehensive sustainability assessment carried out by Cologne-based nova-Institute shows that first and second-generation bioethanol is feasible for the EU’s climate strategy.
The study challenges the tank or table credo of many EU policymakers, which claims biofuels are unsustainable because they use arable land and thus compete with food production.
ADC Therapeutics raises US$200m in private financing
Swiss cancer antibody-drug conjugate (ADC) developer ADC Therapeutics Sarl (Epalinges) has raised US$200m million through an oversubscribed private placement. Investors include Auven Therapeutics, Redmile, the Wild Family Office and its development partner AstraZeneca.
Valuating biotech’s benefits
European Biotech Week:?Highlighting the benefits biotechnology has brought to pharma development, agriculture and – last but not least – the bioeconomy, industry association EuropaBio celebrated the European Biotech Week with an exhibition, Discovering European Biotech Innovation, in the European Parliament in Brussels.
CureVac inks $1.7bn deal on mRNA cancer vaccines
mRNA cancer therapeutics specialist CureVac AG has baged US$50m upfront and is eglible to receive up to US$1.7bn in development milestones plus royalties for the development of five commercial cancer vaccines arising from a new R&D deal with Eli Lilly & Co. Lilly also made an equity investment of €45m.